Stereotactic body radiotherapy for early stage nonsmall cell lung cancer

doi:10.3760/cma.j.issn.1673-422X.2015.10.015

Abstract

Abstract: As one of the treatment options for early stage NSCLC, stereotactic body radiation therapy (SBRT) is mainly applied to the inoperable patients. Compared with small doses of traditional fractionated radiation treatment, SBRT are taken a single high dose of radiation. A large body of experience has been accumulated over the years and the mathematical model to describe survival in high dose range typically used in SBRT and the best dose of segmentation model were focused on, but there has not yet reached a consensus. Studies show that SBRT has certain advantages in local control ratio and adverse reaction compared with traditional radiotherapy, which can be used in operable patients in the future.

Key words: Carcinoma, non-small-cell lung, Radiotherapy, Stereotactic body radiation therapy

Lin Li, Zhou Fuxiang. Stereotactic body radiotherapy for early stage nonsmall cell lung cancer[J]. Journal of International Oncology, 2015, 42(10): 773-775.

References

［1］李宏奇, 王颖杰, 李平, 等. 体部伽马刀治疗早期非小细胞肺癌临床观察［J］. 中华放射肿瘤杂志, 2012, 21(4): 321-324. ［2］ Fernando HC, Timmerman R. American college of surgeons oncology group Z4099/radiation therapy oncology group 1021: a randomized study of sublobar resection compared with stereotactic body radiotherapy for highrisk stage Ⅰ nonsmall cell lung cancer［J］. Thorac Cardiovasc Surg, 2012, 144(3): S35-S38. ［3］ Park C, Papiez L, Zhang S, et al. Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy［J］. Radiat Oncol Biol Phys, 2008, 70(3): 847-852. ［4］ Wang JZ, Huang Z, Lo SS, et al. A generalized linearquadratic model for radiosurgery, stereotactic body radiation therapy, and highdose rate brachytherapy［J］. Sci Transl Med, 2010, 2(39): 39ra48. ［5］ Chi A, Wen S, Liao Z, et al. What would be the most appropriate α/β ratio in the setting of stereotactic body radiation therapy for early stage nonsmall cell lung cancer［J］. Biomed Res Int, 2013, 2013: 391021. ［6］ Senan S, Palma DA, Lagerwaard FJ. Stereotactic ablative radiotherapy for stage Ⅰ NSCLC: recent advances and controversies［J］. J Thorac Dis, 2011, 3(3): 189-196. ［7］ Onishi H, Shirato H, Nagata Y, et al. Stereotactic body radiotherapy (SBRT) for operable stage Ⅰ nonsmallcell lung cancer: can SBRT be comparable to surgery?［J］. Int J Radiat Oncol Biol Phys, 2011, 81(5): 1352-1358. ［8］ Stephans K. Stereotactic body radiotherapy for stage Ⅰ nonsmall cell lung cance［J］. Cleve Clin J Med, 2012, 79 Electronic Suppl 1: eS26-S31. ［9］ Onishi H, Araki T. Stereotactic body radiation therapy for stage Ⅰ nonsmallcell lung cancer: a historical overview of clinical studies［J］. Jpn J Clin Oncol, 2013, 43(4): 345-350. ［10］ Videtic GM, Stephans KL, Woody NM, et al. 30 Gy or 34 Gy comparing 2 singlefraction SBRT dose schedules for stage Ⅰ medically inoperable nonsmall cell lung cancer［J］. Int J Radiat Oncol Biol Phys, 2014, 90(1): 203-208. ［11］ Mutter RW, Liu F, Abreu A, et al. Dosevolume parameters predict for the development of chest wall pain after stereotactic body radiation for lung cancer［J］. Int J Radiat Oncol Biol Phys, 2012, 82(5): 1783-1790. ［12］ Dunlap NE, Cai J, Biedermann GB, et al. Chest wall volume receiving >30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy［J］. Int J Radiat Oncol Biol Phys, 2010, 76(3): 796-801. ［13］ Nagata Y, Wulf J, Lax I, et al. Stereotactic radiotherapy of primary lung cancer and other targets: results of consultant meeting of the International Atomic Energy Agency［J］. Int J Radiat Oncol Biol Phys, 2011, 79(3): 660-669. ［14］ Onishi H, Shirato H, Nagata Y, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage Ⅰ nonsmall cell lung cancer: updated results of 257 patients in a Japanese multiinstitutional study［J］. J Thorac Oncol, 2007, 2(7 Suppl 3): S94-S100. ［15］ Forquer JA, Fakiris AJ, Timmerman RD, et al. Brachial plexopathy from stereotactic body radiotherapy in earlystage NSCLC: doselimiting toxicity in apical tumor sites［J］. Radiother Oncol, 2009, 93(3): 408-413. ［16］ Steven WD, Douglas AR, Ajay PS. Stereotactic body radiation therapy (SBRT) for nonsmall cell lung cancer (NSCLC): current concepts and future directions［J］. Transl Cancer Res, 2014, 3(4): 303-312. ［17］ Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer［J］. JAMA, 2010, 303(11): 1070-1076. ［18］ Grills IS, Mangona VS, Welsh R, et al. Outcomes after stereotactic lung radiotherapy or wedge resection for stage Ⅰ nonsmallcell lung cancer［J］. J Clin Oncol, 2010, 28(6): 928-935. ［19］ Louie AV, Rodrigues G, Hannouf M, et al. Stereotactic body radiotherapy versus surgery for medically operable stage Ⅰ nonsmallcell lung cancer: a markov modelbased decision analysis［J］. Int J Radiat Oncol Biol Phys, 2011, 81(4): 964-973.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[4]	Qian Xiaotao, Shi Ziyi, Hu Ge. A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(3): 151-156.
[5]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing. Progress of radiotherapy in oligometastatic non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(3): 170-174.
[6]	Gao Xinyu, Li Zhenjiang, Sun Hongfu, Han Dan, Zhao Qian, Liu Chengxin, Huang Wei. Clinical application of MR-guided radiotherapy based on MR-linac in esophageal cancer patients [J]. Journal of International Oncology, 2024, 51(1): 37-42.
[7]	Cui Tenglu, Lyu lu, Sun Pengfei. Application of radiotherapy combined with immunotherapy in the treatment of head and neck squamous cell carcinoma [J]. Journal of International Oncology, 2023, 50(9): 548-552.
[8]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer [J]. Journal of International Oncology, 2023, 50(6): 362-367.
[9]	Lyu Lu, Sun Pengfei. Gut flora and cervical cancer [J]. Journal of International Oncology, 2023, 50(6): 373-376.
[10]	Radiation Oncology Treatment Physician Branch, Chinese Medical Doctor Association, Radiation Oncology Therapy Branch, Chinese Medical Association, Chinese Association of Radiation Therapy, China Anti-Cancer Association. Chinese experts' consensus on the application of pegylated recombinant human granulocyte colony-stimulating factor during concurrent chemoradiotherapy （2023 version） [J]. Journal of International Oncology, 2023, 50(4): 193-201.
[11]	Xu Meng, Jiang Wei, Zhu Haitao, Cao Xiongfeng. Research progress of cancer-associated fibroblasts in tumor radiotherapy resistance [J]. Journal of International Oncology, 2023, 50(4): 227-230.
[12]	Shi Xaioqi, Wang Hongyan. Research progress on the interaction between gut microbiota and radiation enteritis [J]. Journal of International Oncology, 2023, 50(4): 244-247.
[13]	Zhao Yongrui, Gao Ying, Chen Yidong, Xu Jiankun. Efficacy and safety of linear accelerator-based fractionated stereotactic radiotherapy for small volume brain metastases [J]. Journal of International Oncology, 2023, 50(3): 138-143.
[14]	Huang Huayu, Gong Hongyun, Song Qibin. Influencing factors of pneumonitis in the period of thoracic radiotherapy combined with immunotherapy [J]. Journal of International Oncology, 2023, 50(2): 102-106.
[15]	Cao Xiaohui, Yu Hong, Li Wanhu. Application of CT-based radiomics analysis in predicting and identifying of treatment-associated pneumonitis [J]. Journal of International Oncology, 2023, 50(2): 107-111.